(Q36167453)

English

A Randomised, Double-Blind, Placebo-Controlled Trial with Vitamin D3 in MS: Subgroup Analysis of Patients with Baseline Disease Activity Despite Interferon Treatment

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

A Randomised, Double-Blind, Placebo-Controlled Trial with Vitamin D3 in MS: Subgroup Analysis of Patients with Baseline Disease Activity Despite Interferon Treatment (English)

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

0 references

placebo-controlled trial

1 reference

based on heuristic

inferred from title

cholecalciferol

1 reference

based on heuristic

inferred from title

author name string

J Aivo

1

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

B-M Lindsröm

2

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

M Soilu-Hänninen

3

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

publication date

5 August 2012

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Multiple Sclerosis International

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

2012

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

802796

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

copyright license

Creative Commons Attribution 3.0 Unported

1 January 2012

1 reference

April 2022 Public Data File from Crossref

copyright status

1 reference

April 2022 Public Data File from Crossref

Higher 25-hydroxyvitamin D is associated with lower relapse risk in multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3420140

1 October 2017

A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3420140

1 October 2017

The importance of early diagnosis of multiple sclerosis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3420140

1 October 2017

Association of vitamin D metabolite levels with relapse rate and disability in multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3420140

2 July 2018

A randomised, double blind, placebo controlled trial with vitamin D3 as an add on treatment to interferon β-1b in patients with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F802796

21 January 2018

Clinical, environmental, and genetic determinants of multiple sclerosis in children with acute demyelination: a prospective national cohort study.

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F802796

21 January 2018

Vitamin D status is associated with relapse rate in pediatric-onset multiple sclerosis

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F802796

21 January 2018

Sun exposure, vitamin D intake and progression to disability among veterans with progressive multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F802796

21 January 2018

The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL.

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F802796

21 January 2018

Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F802796

21 January 2018

Anticipating the future: how the emergence of innovative biologic agents impacts benefit design, utilization, and provider relations

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F802796

21 January 2018

A controlled trial of natalizumab for relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F802796

21 January 2018

Relapse rates and enhancing lesions in a phase II trial of natalizumab in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F802796

21 January 2018

Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F802796

21 January 2018

Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: a meta-analytic approach.

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F802796

21 January 2018

Relapses in multiple sclerosis are age- and time-dependent

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F802796

21 January 2018

Vitamin D metabolites are associated with clinical and MRI outcomes in multiple sclerosis patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/22919492

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of vitamin D3 supplementation on relapses, disease progression, and measures of function in persons with multiple sclerosis: exploratory outcomes from a double-blind randomised controlled trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/22919492

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A longitudinal study of serum 25-hydroxyvitamin D and intact parathyroid hormone levels indicate the importance of vitamin D and calcium homeostasis regulation in multiple sclerosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/22919492

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

25-Hydroxyvitamin D levels in serum at the onset of multiple sclerosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/22919492

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Heterogeneity in response to interferon beta in patients with multiple sclerosis: a 3-year monthly imaging study

1 reference

https://pubmed.ncbi.nlm.nih.gov/22919492

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1155/2012/802796

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36167453&oldid=1800829115"